INTERIM REPORT

July - September

2021

Presentation

CEO Håkan Lagerberg CFO Jenny Graflind

Q3 2021 Highlights

New concepts and new colleagues - a quarter constructing the future

Record sales and profit

Org. growth impacted by delayed Asian orders - less impact going forward

Vetio included from July 1st, visit in Vetio

North

Supply, Production and Project activities

Acquisition of FAV

Key highlights

  • Many bigger business opportunities discussed and agreed
  • Fantastic quarter from many group companies, best quarter for 2021 (UK, Nordic, Spain, Pet MD Brands, Stratford)
  • Solved Brexit challenges, UK-EU
  • Online growth and investments with excellent ROI
  • Vetio sales hampered by hurricane and Covid. Profitability affected by increased raw material cost
  • Finalized expansion of another facility for Vetio South expanding into Supplements and Soft Chew production

Key highlights

  • Closed several Pharma projects starting 2022 for Vetio North
  • Launch of Topicals/dermatology products in Pet Retail channel in USA
  • Move of Pet MD's warehouse - larger, more effective with other group companies
  • Animal Pharm (shift to inhouse Derma production) to Amazon and Chewy and Pet MD® on Amazon UK
  • Dr. Pol license launch on social media starting this week, products on several platforms before Oct/Nov. Major campaigns 2022 with new films released every 2nd week
  • Production of dermatology products in Ireland getting closer and expanding production capabilities for customers

Key Performance Indicators

Q3 2021

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Swedencare AB published this content on 28 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 October 2021 14:02:11 UTC.